Efficacy Comparison of DExamethasone Intravitreal Implant Combined With Aflibercept Versus Aflibercept Monotherapy in Treatment-naïve Inflammatory Diabetic Macular Edema Patients

Exclusion Criteria

• •1. Grade III and IV cataracts, or those with post-comorbid subcapsular cataracts,
• •2. Other macular degeneration such as Macular epiretinal membrane and Macular Hole, etc., or macular edema caused by other causes such as uveitis, retinal vein occlusion, etc.,
• •3. Combined with diabetic optic neuropathy,
• •4. Any prior use of an approved or investigational treatment for DME in the study eye such as anti-VEGF drugs or corticosteroids drugs etc.,
• •5. History of vitreoretinal surgery and/or including scleral buckling in the study eye,
• •6. Transscleral fixated IOLs and ruptured posterior lens capsule,
• •7. Active or suspected ocular and periocular infections,
• •8. Advanced glaucoma or uncontrolled glaucoma with anti-glaucoma drugs; Or a history of glucocorticoid-induced elevated intraocular pressure,
• •9. Systemic conditions such as asthma, severe hypertension, cerebrovascular accident or myocardial infarction, or other reasons for not being able to co-operate with the relevant examination,
• •10. Pregnant or lactating,
• •11. Patients with hypersensitivity to dexamethasone or to any other components of the product,
• •12. Patients are allergic to aflibercept or any of the ingredients Aflibercept Intravitreous Injection.